Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cytodyn Inc
(OP:
CYDY
)
0.1265
UNCHANGED
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cytodyn Inc
< Previous
1
2
3
Next >
CytoDyn Files for Expanded Access Use of Leronlimab for Multi-Drug Resistance HIV Patients
December 09, 2021
From
CytoDyn Inc.
Via
Business Wire
CytoDyn’s CRO in Brazil Met with ANVISA to Modify CD16 Trial for Critically Ill COVID-19 Patients to Expedite Interim Analysis After 51 Patients, Potentially in 1Q2022
December 08, 2021
From
CytoDyn Inc.
Via
Business Wire
CytoDyn Submits CMC (Manufacturing) Section of HIV BLA to FDA Under Previously Authorized Rolling Review; Last (Clinical) Section Will Complete Full BLA Submission
December 01, 2021
From
CytoDyn Inc.
Via
Business Wire
CytoDyn’s Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at World Antiviral Congress 2021 Beginning Tomorrow
November 29, 2021
From
CytoDyn Inc.
Via
Business Wire
Leronlimab (350 mg) Weekly Use for 14 Weeks in Open Label Arm of NASH Trial Produces Fibrosis Reduction as High as 93 msec Amongst First 15 Patients with Average Reduction of 24 msec
November 24, 2021
From
CytoDyn Inc.
Via
Business Wire
CytoDyn Research Paper on Leronlimab Published in Frontiers in Immunology Journal
November 19, 2021
From
CytoDyn Inc.
Via
Business Wire
Health Canada Authorizes Emergency Use of Leronlimab for Treatment of First Triple-Negative Breast Cancer Patient in Canada
November 16, 2021
From
CytoDyn Inc.
Via
Business Wire
CytoDyn Inc. Announces Adjournment of Annual Meeting of Shareholders to November 24, 2021 Due to Lack of Quorum
October 28, 2021
From
CytoDyn Inc.
Via
Business Wire
CytoDyn Announces Delaware Court Has Denied Activist Group’s Motion to Prevent Annual Meeting from Taking Place
October 20, 2021
From
CytoDyn Inc.
Via
Business Wire
CytoDyn Alerts Shareholders to Vote on Company’s Proxy Card Ahead of October 28th Annual Meeting
October 18, 2021
From
CytoDyn Inc.
Via
Business Wire
Group of CytoDyn Stockholders Comments on Delaware Court Decision
October 14, 2021
From
Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via
Business Wire
Delaware Court Agrees with CytoDyn that Activist Group’s Nominations are Invalid
October 14, 2021
From
CytoDyn Inc.
Via
Business Wire
CytoDyn Comments on Rosenbaum/Patterson Activist Group “Plan”
September 29, 2021
From
CytoDyn Inc.
Via
Business Wire
Group of CytoDyn Stockholders Releases White Paper Regarding Company’s Extremely Unfavorable Borrowing Practices
September 27, 2021
From
Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via
Business Wire
CytoDyn to Present at Emerging Growth Conference on September 29 Followed by Live Q/A
September 27, 2021
From
CytoDyn Inc.
Via
Business Wire
Group of CytoDyn Stockholders Shares Strategic Plan to Obtain Cancer Therapy Approval for Leronlimab
September 24, 2021
From
Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via
Business Wire
Accelerated Development of COVID-19 Vaccines to Combat Potential for Possible Future Viral Pathogens and Variants
September 22, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
CytoDyn Receives Clearance from Brazil’s FDA (ANVISA) to Commence a Pivotal Phase 3 Trial in Critically Ill COVID-19 Patients with IV Administration of Four Doses (700mg/week)
September 22, 2021
From
CytoDyn Inc.
Via
Business Wire
CytoDyn’s Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at the World Antiviral Congress 2021
September 21, 2021
From
CytoDyn Inc.
Via
Business Wire
Group of CytoDyn Stockholders Announces Federal Court Dismisses Litigation Brought by Company
September 20, 2021
From
Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via
Business Wire
CytoDyn Announces Resolution of Federal Litigation with Rosenbaum/Patterson Activist Group
September 20, 2021
From
CytoDyn Inc.
Via
Business Wire
Bruce Patterson, M.D., Director Candidate for CytoDyn Board, Presents at International COVID Summit
September 17, 2021
From
Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via
Business Wire
Glancy Prongay & Murray LLP Announces Investigation of CytoDyn Inc.
September 15, 2021
From
Glancy Prongay & Murray LLP
Via
Business Wire
Group of CytoDyn Stockolders Responds to Misleading Company News Release
September 07, 2021
From
Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via
Business Wire
CytoDyn Highlights Court Ordering Rosenbaum/Patterson Group to Comply With the Federal Securities Laws
September 02, 2021
From
CytoDyn Inc.
Via
Business Wire
Why Experts Believe Antibody Treatments Hold The Potential To Reduce Need For Hospitalization For COVID-19 Patients
September 14, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
Group of CytoDyn Stockholders Warns Stockholders of Board’s Continued Value Destruction and Failures
September 02, 2021
From
Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via
Business Wire
Group of CytoDyn Stockholders Files Lawsuit to Force Company to Allow Stockholders to Vote for Alternative Director Nominees
August 26, 2021
From
Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via
Business Wire
CytoDyn Urges Shareholders to Ignore Proxy Cards from Rosenbaum/Patterson Group
August 25, 2021
From
CytoDyn
Via
Business Wire
Group of CytoDyn Stockholders Responds to Highly Misleading Company Release
August 19, 2021
From
Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.